Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25918195 | 0.77 | PRMT5 (0.48) | TACR1PRMT5WDR77RIPK1FABP7 | |
| SCHEMBL25321619 | 0.77 | PRMT5 (0.48) | TACR1PRMT5WDR77RIPK1FABP7 | |
| SCHEMBL25321623 | 0.77 | PRMT5 (0.48) | TACR1PRMT5WDR77RIPK1FABP7 | |
| SCHEMBL25322924 | 0.76 | PRMT5 (0.58) | TACR1PRMT5WDR77RIPK1 | |
| SCHEMBL24366565 | 0.76 | PRMT5 (0.47) | TACR1PRMT5WDR77RIPK1FABP7 | |
| Ammonia Solution, Strong SCHEMBL25321406 | 0.75 | PRMT5 (0.57) | TACR1PRMT5WDR77RIPK1 | |
| SCHEMBL25323773 | 0.74 | PRMT5 (0.45) | TACR1PRMT5WDR77RIPK1FABP7 | |
| SCHEMBL30551470 | 0.74 | PRMT5 (0.45) | TACR1PRMT5WDR77RIPK1FABP7 | |
| SCHEMBL25322227 | 0.74 | PRMT5 (0.47) | PRMT5WDR77RIPK1FABP7SCN9A | |
| SCHEMBL25322230 | 0.74 | PRMT5 (0.47) | PRMT5WDR77RIPK1FABP7SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | TACR1 310/4885PRMT5 562/4885WDR77 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.